Abstract
The role of the breast surgeon continues to evolve in an era of improved precision pharmacological agents combating breast cancer and de-escalation of locoregional treatments. Surgical breast oncologists should lead the effort to create preventive strategies and help to improve the uptake of risk-reducing medications (RRMEDS) for women at higher risk of developing breast cancer. Helping women to understand their risk of developing breast cancer will help the initiation of RRMEDS. Fear of side effects caused by these RRMEDS remains a significant obstacle for uptake. Low-dose tamoxifen has shown to help mitigate side effects and reduce attrition rate of women who initiated therapy and should be considered as part of the surgeon's armamentarium for RRMEDS.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
